Frequently asked questions about injectable NAD+

Nicotinamide adenine dinucleotide — a dinucleotide cofactor found in every living cell. It shuttles electrons in metabolism and is consumed as a substrate by sirtuins (NAD-dependent deacetylases, Imai/Guarente 2000) and by PARP enzymes during DNA repair. Tissue NAD+ declines with age (Massudi et al. 2012).

Panacea Bio Chem's improved injectable NAD+ formulation, supplied in the Lyoprester SS single-shot dual-chamber cartridge: the lyophilized NAD+ cake and its solvent stay apart until one action reconstitutes the dose aseptically at the point of use.

Intact oral NAD+ is largely degraded in the gut and liver before reaching circulation — which is why most oral products are precursors (NMN or NR) that the body must convert. Injection bypasses first-pass digestion and delivers the intact molecule directly. The oral-bioavailability debate is ongoing in the literature; the injection format sidesteps it.

Panacea's single-shot dual-chamber, pre-filled cartridge. The freeze-dried cake sits in one chamber and the solvent in the other, separated by an internal septum; a single action breaches the septum and reconstitutes the dose. No diluent vial, no open transfer, no manual mixing — an aseptic one-action reconstitution.

They are Panacea's formulation-protection technologies: TgShift actively raises the glass-transition temperature so the cake can be dried warmer and faster without collapse; OxyDeplete degasses the formulation and removes headspace so no oxygen reservoir remains; ArgonLock backfills the finished dry cake under argon; RedoxVault physically isolates redox-sensitive material from reactive contact.

Yes. Intact NAD+ rather than a precursor, injectable rather than oral, protected during storage and reconstituted fresh in one aseptic action by the Lyoprester SS dual chamber. No other format on the market does all of that — this is Panacea's position, and the engineering behind it is on this site.

For precursors: Martens et al. (University of Colorado Boulder, 2018) showed chronic NR supplementation raises NAD+ in healthy middle-aged and older adults; Irie et al. (Keio University, 2020) reported oral NMN tolerability and metabolite changes in healthy men. Long-term outcome questions remain open — the 2018 Rajman, Chwalek & Sinclair review states them plainly.

Arthur Harden and William John Young identified the fermentation coenzyme (co-zymase) at the Lister Institute in 1906; Harden shared the 1929 Nobel Prize in Chemistry for the work. The full credited timeline is on The Story.